Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours

BMC Cancer

Karyn S Ho²  Peter C Poon³  Shawn C Owen²  Molly S Shoichet¹ 

[1] Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON, M5S 3H6, Canada

[2] Institute of Biomaterials & Biomedical Engineering, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Room 514 – 160 College Street, Toronto, ON, M5S 3E1, Canada

[3] Department of Chemical Engineering & Applied Chemistry, 200 College Street, Toronto, ON, M5S 3E5, Canada

关键词: Targeting;    Nanomedicine;    Blood vessel hyperpermeability;    Breast cancer;    Enhanced permeability and retention;    Ectopic transplantation;    Orthotopic transplantation;    Tumour xenograft models;   

Others  :  1080035
DOI  :  10.1186/1471-2407-12-579

 received in 2012-06-21, accepted in 2012-11-12,  发布年份 2012

【 摘 要 】

Background

Human tumour xenografts in immune compromised mice are widely used as cancer models because they are easy to reproduce and simple to use in a variety of pre-clinical assessments. Developments in nanomedicine have led to the use of tumour xenografts in testing nanoscale delivery devices, such as nanoparticles and polymer-drug conjugates, for targeting and efficacy via the enhanced permeability and retention (EPR) effect. For these results to be meaningful, the hyperpermeable vasculature and reduced lymphatic drainage associated with tumour pathophysiology must be replicated in the model. In pre-clinical breast cancer xenograft models, cells are commonly introduced via injection either orthotopically (mammary fat pad, MFP) or ectopically (subcutaneous, SC), and the organ environment experienced by the tumour cells has been shown to influence their behaviour.

Methods

To evaluate xenograft models of breast cancer in the context of EPR, both orthotopic MFP and ectopic SC injections of MDA-MB-231-H2N cells were given to NOD scid gamma (NSG) mice. Animals with matched tumours in two size categories were tested by injection of a high molecular weight dextran as a model nanocarrier. Tumours were collected and sectioned to assess dextran accumulation compared to liver tissue as a positive control. To understand the cellular basis of these observations, tumour sections were also immunostained for endothelial cells, basement membranes, pericytes, and lymphatic vessels.

Results

SC tumours required longer development times to become size matched to MFP tumours, and also presented wide size variability and ulcerated skin lesions 6 weeks after cell injection. The 3 week MFP tumour model demonstrated greater dextran accumulation than the size matched 5 week SC tumour model (for P < 0.10). Immunostaining revealed greater vascular density and thinner basement membranes in the MFP tumour model 3 weeks after cell injection. Both the MFP and SC tumours showed evidence of insufficient lymphatic drainage, as many fluid-filled and collagen IV-lined spaces were observed, which likely contain excess interstitial fluid.

Conclusions

Dextran accumulation and immunostaining results suggest that small MFP tumours best replicate the vascular permeability required to observe the EPR effect in vivo. A more predictable growth profile and the absence of ulcerated skin lesions further point to the MFP model as a strong choice for long term treatment studies that initiate after a target tumour size has been reached.

【 授权许可】

   
2012 Ho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Teicher BA: Human tumor xenografts and mouse models of human tumors: re-discovering the models. Expert Opin Drug Dis 2009, 4(12):1295-1305.
• [2]Torchilin V: Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliver Rev 2011, 63(3):131-135.
• [3]Fang J, Nakamura H, Maeda H: The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 2011, 63(3):136-151.
• [4]Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
• [5]Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21(3):505-515.
• [6]Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12):6387-6392.
• [7]Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160(3):985-1000.
• [8]Dreher MR, Liu WG, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer I 2006, 98(5):335-344.
• [9]Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
• [10]Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156(4):1363-1380.
• [11]Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang MY, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, et al.: A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69(13):5296-5300.
• [12]Hida K, Hida Y, Shindoh M: Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99(3):459-466.
• [13]McDonald DM, Baluk P: Significance of blood vessel leakiness in cancer. Cancer Res 2002, 62(18):5381-5385.
• [14]Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163(5):1801-1815.
• [15]Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406.
• [16]Wu J, Akaike T, Maeda H: Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998, 58(1):159-165.
• [17]Kerbel RS, Cornil I, Theodorescu D: Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor-growth and metastasis. Cancer Metast Rev 1991, 10(3):201-215.
• [18]Killion JJ, Radinsky R, Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metast Rev 1998, 17(3):279-284.
• [19]Lunt SJ, Kalliomaki TMK, Brown A, Yang VX, Milosevic M, Hill RP: Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 2008, 8:2. BioMed Central Full Text
• [20]Wilmanns C, Fan D, Obrian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon-carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992, 52(1):98-104.
• [21]Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS: Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011, 11(2):135-141.
• [22]Holliday DL, Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res 2011, 13(4):215. BioMed Central Full Text
• [23]Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
• [24]Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (Nude) mice. Cancer Chemoth Pharm 1989, 24(3):148-154.
• [25]Schiffelers RM, Metselaar JM, Fens MHAM, Janssen APCA, Molema G, Storm G: Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 2005, 7(2):118-127.
• [26]Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al.: NOD/SCID/gamma(null)(c) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100(9):3175-3182.
• [27]Cogger VC, McNerney GP, Nyunt T, DeLeve LD, McCourt P, Smedsrod B, Le Couteur DG, Huser TR: Three-dimensional structured illumination microscopy of liver sinusoidal endothelial cell fenestrations. J Struct Biol 2010, 171(3):382-388.
• [28]Davies B, Morris T: Physiological parameters in laboratory-animals and humans. Pharmaceut Res 1993, 10(7):1093-1095.
• [29]Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y: Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 2000, 91(2):261-269.
• [30]Chen B, Pogue BW, Zhou XD, O'Hara JA, Solban N, Demidenko E, Hoopes PJ, Hasan T: Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005, 11(2):720-727.
• [31]Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64(11):3731-3736.
• [32]Kong G, Braun RD, Dewhirst MW: Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000, 60(16):4440-4445.
• [33]Abdelkarim M, Vintonenko N, Starzec A, Robles A, Aubert J, Martin M-L, Mourah S, Podgorniak M-P, Rodrigues-Ferreira S, Nahmias C, et al.: Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype. PLoS One 2011, 6(8):e23334.
• [34]Perles-Barbacaru AT, van der Sanden BPJ, Farion R, Lahrech H: How stereological analysis of vascular morphology can quantify the blood volume fraction as a marker for tumor vasculature: comparison with magnetic resonance imaging. J Cerebr Blood F Met 2012, 32(3):489-501.
• [35]Rockson SG: Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008, 52(10):799-806.
• [36]Schneider M, Ny A, Ruiz De Almodovar C, Carmeliet P: A new mouse model to study acquired lymphedema. PLoS Med 2006, 3(7):e264.
• [37]Szuba A, Rockson SG: Lymphedema: anatomy, physiology and pathogenesis. Vasc Med 1997, 2(4):321-326.